<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Early Detection &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/early-detection/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 22 Jan 2026 23:16:05 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Early Detection &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Efficient Plasma Assay Enhances Early Alzheimer’s Detection</title>
		<link>https://bioengineer.org/efficient-plasma-assay-enhances-early-alzheimers-detection/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 23:15:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Alzheimer's disease biomarkers]]></category>
		<category><![CDATA[Based on the content focusing on a new]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[efficient plasma test for early Alzheimer's detection using mass spectrometry]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Alzheimer's early detection]]></category>
		<category><![CDATA[Mass Spectrometry Applications]]></category>
		<category><![CDATA[Mass spectrometry diagnostics]]></category>
		<category><![CDATA[Plasma Assay Technology]]></category>
		<category><![CDATA[Plasma biomarker assay]]></category>
		<category><![CDATA[Preclinical Diagnosis]]></category>
		<guid isPermaLink="false">https://bioengineer.org/efficient-plasma-assay-enhances-early-alzheimers-detection/</guid>

					<description><![CDATA[In the relentless pursuit of early detection methods for Alzheimer’s disease, a groundbreaking study has emerged, unveiling a resource-efficient, streamlined plasma amyloid-beta assay that offers unprecedented sensitivity and accuracy in preclinical diagnosis. This advancement could herald a new era in biomarker-based detection of Alzheimer’s, a neurodegenerative disease that has long challenged clinicians and researchers due [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319529</post-id>	</item>
		<item>
		<title>Metabolomics Predicts Prostate Cancer Risk: Review Insights</title>
		<link>https://bioengineer.org/metabolomics-predicts-prostate-cancer-risk-review-insights/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 14:22:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer biomarkers]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Metabolomics]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[systematic review]]></category>
		<guid isPermaLink="false">https://bioengineer.org/metabolomics-predicts-prostate-cancer-risk-review-insights/</guid>

					<description><![CDATA[The intricate role of metabolomic dysregulation in the pathogenesis of prostate cancer (PCa) has emerged as a focal point of investigation within the oncological community. Recent studies illuminate the promising potential of circulating metabolites as clinical biomarkers, which could represent a transformative advancement in early cancer detection and management. While the concept of using biochemical [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318964</post-id>	</item>
		<item>
		<title>Evaluating Nevi Count: A Tool for Total Body Assessment</title>
		<link>https://bioengineer.org/evaluating-nevi-count-a-tool-for-total-body-assessment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 17 Jan 2026 08:10:43 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Nevus Count]]></category>
		<category><![CDATA[Skin cancer risk]]></category>
		<category><![CDATA[systematic review]]></category>
		<guid isPermaLink="false">https://bioengineer.org/evaluating-nevi-count-a-tool-for-total-body-assessment/</guid>

					<description><![CDATA[In recent years, skin cancer has become an increasing concern for numerous individuals across the globe. Among various risk factors associated with skin cancer, the relationship of nevi (moles) and their count on the body has sparked considerable research interest. A systematic review by To et al. has shed light on this critical area by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">317718</post-id>	</item>
		<item>
		<title>JNK3 Levels in Plasma Signal Parkinson’s Neuronal Damage</title>
		<link>https://bioengineer.org/jnk3-levels-in-plasma-signal-parkinsons-neuronal-damage/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 02:41:31 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[JNK3 protein]]></category>
		<category><![CDATA[Neuronal damage]]></category>
		<category><![CDATA[Parkinson's disease biomarkers]]></category>
		<category><![CDATA[Plasma diagnostics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/jnk3-levels-in-plasma-signal-parkinsons-neuronal-damage/</guid>

					<description><![CDATA[In an exciting development that could revolutionize the early diagnosis and monitoring of Parkinson’s disease, scientists have unveiled a groundbreaking biomarker detectable in blood plasma: JNK3. This novel approach promises to transform the landscape of neurodegenerative disease diagnostics by offering a less invasive, more accessible means of assessing neuronal damage at the molecular level. Parkinson’s [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">305381</post-id>	</item>
		<item>
		<title>Emerging Biochemical Markers Enhance Ovarian Cancer Diagnosis</title>
		<link>https://bioengineer.org/emerging-biochemical-markers-enhance-ovarian-cancer-diagnosis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 02 Dec 2025 19:11:26 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[biochemical markers]]></category>
		<category><![CDATA[Biyobelirteç tabanlı teşhis]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[erken evre teşhis gelişmeleri]]></category>
		<category><![CDATA[invaziv olmayan kanser tarama]]></category>
		<category><![CDATA[Kişiselleştirilmiş onkoloji]]></category>
		<category><![CDATA[klinik onkoloji inovasyonu]]></category>
		<category><![CDATA[non-invasive diagnostics]]></category>
		<category><![CDATA[Ovarian Cancer Diagnosis]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/emerging-biochemical-markers-enhance-ovarian-cancer-diagnosis/</guid>

					<description><![CDATA[In a groundbreaking study that could revolutionize the way ovarian carcinoma is diagnosed and monitored, researchers have identified four novel biochemical markers that show promise in significantly enhancing early detection and prognosis of this often-deadly disease. This advancement could lead to improved treatment strategies and ultimately save lives. Ovarian carcinoma remains one of the most [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">304455</post-id>	</item>
		<item>
		<title>AI-Driven Ovarian Cancer Diagnosis: Spotlight on SOX17</title>
		<link>https://bioengineer.org/ai-driven-ovarian-cancer-diagnosis-spotlight-on-sox17/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 04 Nov 2025 12:41:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Machine learning in oncology]]></category>
		<category><![CDATA[Ovarian Cancer Diagnosis]]></category>
		<category><![CDATA[Precision Medicine]]></category>
		<category><![CDATA[SOX17 Biomarker]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ai-driven-ovarian-cancer-diagnosis-spotlight-on-sox17/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have unveiled an innovative diagnostic model for ovarian cancer that leverages the power of machine learning algorithms combined with an in-depth analysis of the essential biomarker SOX17. This research is not just a mere academic exercise; it represents a potential game-changer in how ovarian cancer may be diagnosed and treated [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">291080</post-id>	</item>
		<item>
		<title>AP3B1 and BMPR2: New Parkinson’s Blood Biomarkers</title>
		<link>https://bioengineer.org/ap3b1-and-bmpr2-new-parkinsons-blood-biomarkers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 28 Oct 2025 15:54:10 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[AP3B1 and BMPR2]]></category>
		<category><![CDATA[Blood-Based Diagnostics]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Neurodegenerative Research]]></category>
		<category><![CDATA[Parkinson's disease biomarkers]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ap3b1-and-bmpr2-new-parkinsons-blood-biomarkers/</guid>

					<description><![CDATA[In a groundbreaking advancement poised to reshape Parkinson’s disease diagnostics, researchers have identified a synergistic blood-based biomarker duo, AP3B1 and BMPR2, that could significantly enhance early detection accuracy. This study, recently published in npj Parkinson’s Disease, illuminates a transformative approach to diagnosing Parkinson’s through minimally invasive blood tests, addressing a longstanding challenge in the field. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287820</post-id>	</item>
		<item>
		<title>CA 15-3 and CEA Tumor Markers Used in the Diagnosis and Monitoring of Cancer</title>
		<link>https://bioengineer.org/ca-15-3-and-cea-tumor-markers-used-in-the-diagnosis-and-monitoring-of-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 14 Jan 2024 16:53:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Bone Metastases]]></category>
		<category><![CDATA[CA 15-3]]></category>
		<category><![CDATA[Cancer Diagnosis]]></category>
		<category><![CDATA[Cancer Management]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[Carcinoembryonic Antigen]]></category>
		<category><![CDATA[CEA Tumor Markers]]></category>
		<category><![CDATA[CEACAM Family]]></category>
		<category><![CDATA[Cell Adhesion]]></category>
		<category><![CDATA[Early Detection]]></category>
		<category><![CDATA[Epithelial Cells]]></category>
		<category><![CDATA[Exon 19 Mutations]]></category>
		<category><![CDATA[Glycosylation]]></category>
		<category><![CDATA[HER2-Enriched]]></category>
		<category><![CDATA[Immunoglobulin Domains]]></category>
		<category><![CDATA[Liver Metastases]]></category>
		<category><![CDATA[Luminal Subtypes]]></category>
		<category><![CDATA[Metastasis]]></category>
		<category><![CDATA[Metastasis Location]]></category>
		<category><![CDATA[MUC1 Glycoprotein]]></category>
		<category><![CDATA[Pleural Effusions]]></category>
		<category><![CDATA[Quality of Life]]></category>
		<category><![CDATA[Serum Markers]]></category>
		<category><![CDATA[Treatment Response]]></category>
		<category><![CDATA[Triple Negative]]></category>
		<category><![CDATA[Tumor Burden]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=219284</guid>

					<description><![CDATA[CA 15-3 is an epitope of the MUC1 glycoprotein. MUC1 is a transmembrane mucosa-associated glycoprotein and contains a large extracellular domain, a transmembrane region and a cytoplasmic tail. The extracellular portion of MUC1 consists of numerous tandemly repeating peptide sequences. These repeats lead to a long and protruding structure of the protein and form a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">219284</post-id>	</item>
	</channel>
</rss>
